Resonetics® Completes the Acquisition of Resolution Medical, Expanding End-to-End Integrated Capabilities for Interventional and Neuromodulation Markets

Rhea-AI Summary

Resonetics (NYSE:CG) completed the acquisition of Resolution Medical on March 23, 2026, expanding end-to-end design, finished device and sub-assembly capabilities for interventional, structural heart, and neuromodulation markets.

The deal integrates Resolution Medical's biosimulation, NPI, and cleanroom assembly expertise with Resonetics' AGILE Product Development, precision manufacturing, advanced materials, and battery technologies to offer more seamless lifecycle support from concept through scaled production.

Positive

• Expanded capabilities across design, finished device and sub-assembly
• Integrated biosimulation and NPI combined with AGILE Product Development
• Strengthened support for interventional, structural heart, and neuromodulation markets
• Enhanced battery and IPG/EPG manufacturing investments integrated into offerings
• Global manufacturing depth and broader technical capabilities for OEMs

Negative

• None.

News Market Reaction – CG

+1.17%

1 alert

+1.17% News Effect

On the day this news was published, CG gained 1.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $47.23 Vol: Volume 1,415,971 is below...

low vol

$47.23 Last Close

Volume Volume 1,415,971 is below the 20-day average of 3,659,848 (relative volume 0.39). low

Technical Shares at $47.10 are trading below the 200-day MA of $57.63 and 32.57% under the 52-week high.

Peers on Argus

CG was down 1.24% with mixed peers: TPG -2.29%, TROW -0.87%, OWL -0.33%, while N...

CG was down 1.24% with mixed peers: TPG -2.29%, TROW -0.87%, OWL -0.33%, while NTRS +0.22% and RJF +0.75%, suggesting stock-specific drivers.

Previous Acquisition Reports

5 past events · Latest: Feb 18 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 18	Acquisition closing	Positive	+1.2%	Reddy Ice closed Arctic Glacier acquisition, expanding packaged ice footprint.
Jan 30	Acquisition agreement	Positive	-1.2%	Reddy Ice agreed to acquire Arctic Glacier pending regulatory approvals.
Jan 27	Acquisition agreement	Positive	-1.4%	Resonetics agreed to acquire Resolution Medical, adding neuromodulation capabilities.
Jan 06	Asset acquisition	Positive	+2.5%	Resonetics bought Med-Ally IPG/EPG assets, deepening bioelectronics implant offering.
Dec 18	Acquisition announcement	Positive	+1.4%	Howard Hughes agreed to acquire Vantage Group Holdings for $2.1 billion cash.

Pattern Detected

Acquisition headlines for CG-linked assets have produced generally modest moves, with a mix of small gains and losses around ±1–3%.

Recent Company History

Over the past few months, CG-related platforms have been active in M&A, including Reddy Ice’s Arctic Glacier deal and multiple Resonetics acquisitions in bioelectronics and neuromodulation. Price reactions to these acquisition events ranged from about -1.45% to +2.53%, indicating measured market responses. Today’s completion of the Resolution Medical acquisition extends that strategic build‑out in neuromodulation and structural heart solutions, fitting into an ongoing portfolio-expansion narrative rather than a standalone pivot.

Historical Comparison

+0.5% avg move · In the past several CG-linked acquisition announcements, price moves averaged about 0.5%, with indiv...

acquisition

+0.5%

Average Historical Move acquisition

In the past several CG-linked acquisition announcements, price moves averaged about 0.5%, with individual reactions between roughly -1.45% and +2.53%, suggesting typically modest trading responses.

For Resonetics, acquisitions have expanded from Med-Ally’s IPG/EPG assets into the full Resolution Medical platform, reinforcing a stepwise build-out in neuromodulation and structural heart device capabilities.

Market Pulse Summary

This announcement details Resonetics’ completion of the Resolution Medical acquisition, deepening it...

Analysis

This announcement details Resonetics’ completion of the Resolution Medical acquisition, deepening its integrated capabilities in neuromodulation, structural heart, and interventional markets. It builds on prior CG-linked transactions that expanded bioelectronics implant and IPG/EPG manufacturing capacity. Investors may focus on how the combined design, biosimulation, and cleanroom assembly platform supports end-to-end device programs and whether integration of these assets enhances long-term margins and growth across regulated medical device markets.

Key Terms

neuromodulation, biosimulation, cleanroom, implantable and external pulse generator (IPG / EPG), +1 more

5 terms

neuromodulation medical

"high-growth areas such as neuromodulation, where close coordination across device design"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

biosimulation medical

"By incorporating Resolution Medical's biosimulation, design, new product introduction (NPI)"

Biosimulation is the use of computer models to mimic how drugs, cells, or whole biological systems behave, predicting outcomes like effectiveness, side effects, or disease progression. Think of it as a flight or weather simulator for biology that lets researchers test ideas virtually before real-world trials. Investors care because accurate biosimulation can cut development time and cost, lower the risk of failed trials, and improve the odds that a program will reach the market.

cleanroom technical

"new product introduction (NPI), and cleanroom assembly expertise with Resonetics'"

A cleanroom is a tightly controlled workspace where air, particles, microbes, temperature and humidity are kept within strict limits to prevent contamination during manufacturing, testing or research—commonly used for pharmaceuticals, biotech, medical devices and semiconductors. Investors care because a well-designed and operated cleanroom reduces product defects, supports regulatory approval and enables reliable scale-up; think of it as a sterile kitchen that protects delicate recipes, lowering recall risk and helping preserve revenue and margins.

implantable and external pulse generator (IPG / EPG) medical

"implantable and external pulse generator (IPG / EPG) manufacturing, expanding in and supporting"

An implantable pulse generator (IPG) or external pulse generator (EPG) is a medical device that sends controlled electrical pulses to nerves or organs to change their activity, like a pacemaker for the heart or a remote control for pain and movement signals. IPGs are placed inside the body; EPGs sit outside and connect wirelessly or through leads. Investors care because these devices drive sales, affect surgical and device-cost risks, regulatory approval paths, and long-term service and reimbursement dynamics.

oems technical

"platform that helps OEMs reduce complexity, improve execution, and bring innovative"

OEMs, or Original Equipment Manufacturers, are companies that produce the main components or products that other companies use to build finished goods. For investors, OEMs are important because their performance can influence the supply chain, manufacturing costs, and overall market trends in industries like technology, automotive, and electronics. Their success often reflects broader economic health and consumer demand.

AI-generated analysis. Not financial advice.

NASHUA, N.H., March 23, 2026 /PRNewswire/ -- Resonetics^® announced today the successful completion of its acquisition of Resolution Medical, which further strengthens its ability to deliver integrated, end-to-end device solutions for customers in the interventional, structural heart, and neuromodulation markets.

The acquisition expands Resonetics' design, finished device and sub-assembly capabilities, enabling broader support across the full product lifecycle from early concept and development through commercialization and scaled production. By incorporating Resolution Medical's biosimulation, design, new product introduction (NPI), and cleanroom assembly expertise with Resonetics' AGILE Product Development^® group, precision component manufacturing, advanced materials, and battery technologies, Resonetics creates a more seamless platform that helps OEMs reduce complexity, improve execution, and bring innovative devices to market faster.

"This marks an important milestone in Resonetics' growth strategy," said Kevin Kelly, CEO of Resonetics. "As device complexity increases, our customers are looking for partners who can take greater ownership across development and manufacturing. Bringing Resolution Medical into the Resonetics platform strengthens our ability to execute integrated programs at scale and support the next generation of innovative therapies."

The combination further strengthens Resonetics' ability to support customers in high-growth areas such as neuromodulation, where close coordination across device design, electronics, batteries, and assembly is essential. With expanded integration and collaboration, customers benefit from more efficient program execution and greater confidence as devices progress toward commercialization.

"Joining Resonetics allows us to amplify what we do best," said Peter Herman, CEO of Resolution Medical. "Our team has built a strong reputation for solving complex engineering challenges. Now, as part of Resonetics, we can extend that impact by leveraging broader manufacturing depth, integrated component content, global resources, and expanded technical capabilities while continuing to deliver the responsiveness and expertise our customers expect."

The acquisition builds on Resonetics' recent investments in battery, lead, and implantable and external pulse generator (IPG / EPG) manufacturing, expanding in and supporting more comprehensive device solutions. Together, the combined organization positions Resonetics as a strategic partner to serve customers innovating complex, regulated medical devices that demand both technical depth and manufacturing scale.

About Resonetics
Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs^® and AGILE Product Development^® centers, Resonetics is committed to quality, speed, innovation, and a great customer experience. The company is ISO 13485:2016 certified with 18 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR. Learn more at www.resonetics.com.

About GTCR
Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and operates through three segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $477 billion of assets under management as of December 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,500 people in 27 offices across four continents. Further information is available at carlyle.com. Follow Carlyle on LinkedIn at The Carlyle Group and on X at @OneCarlyle.

View original content to download multimedia:https://www.prnewswire.com/news-releases/resonetics-completes-the-acquisition-of-resolution-medical-expanding-end-to-end-integrated-capabilities-for-interventional-and-neuromodulation-markets-302719940.html

SOURCE Resonetics, LLC

FAQ

What did Resonetics (CG) announce on March 23, 2026 regarding Resolution Medical?

Resonetics announced it completed the acquisition of Resolution Medical on March 23, 2026, expanding integrated device capabilities. According to the company, the acquisition brings biosimulation, NPI, and cleanroom assembly into Resonetics' platform to support end-to-end device lifecycles.

How will the Resolution Medical acquisition affect Resonetics (CG) capabilities in neuromodulation?

The acquisition expands Resonetics' ability to support neuromodulation through tighter device, electronics, battery, and assembly coordination. According to the company, this integration aims to improve program execution and speed devices toward commercialization.

What specific capabilities does Resonetics (CG) gain from Resolution Medical?

Resonetics gains biosimulation, design, new product introduction (NPI), and cleanroom assembly expertise from Resolution Medical. According to the company, these capabilities complement Resonetics' AGILE Product Development, precision components, advanced materials, and battery technologies.

Does the acquisition change Resonetics (CG) product lifecycle support for OEM customers?

Yes. The acquisition extends end-to-end support from early concept through scaled production for OEMs. According to the company, the combined platform aims to reduce program complexity and improve execution across the full product lifecycle.

How does the acquisition relate to Resonetics (CG) recent investments in batteries and IPG/EPG manufacturing?

The acquisition builds on recent Resonetics investments in battery, lead, and IPG/EPG manufacturing to offer more comprehensive device solutions. According to the company, combining these capabilities creates a more seamless platform for regulated medical devices.

What benefits did Resonetics (CG) say customers should expect after the acquisition?

Customers should expect more efficient program execution, reduced complexity, and greater confidence as devices move toward commercialization. According to the company, the combined teams deliver broader manufacturing depth and integrated technical capabilities for OEMs.